WealthShield Partners LLC Acquires 1,468 Shares of IDEXX Laboratories, Inc. $IDXX

WealthShield Partners LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 114.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,746 shares of the company’s stock after buying an additional 1,468 shares during the period. WealthShield Partners LLC’s holdings in IDEXX Laboratories were worth $1,473,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in IDEXX Laboratories by 5.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,724 shares of the company’s stock worth $10,579,000 after acquiring an additional 998 shares during the last quarter. Foundations Investment Advisors LLC increased its position in shares of IDEXX Laboratories by 38.9% during the 2nd quarter. Foundations Investment Advisors LLC now owns 914 shares of the company’s stock valued at $490,000 after purchasing an additional 256 shares during the last quarter. Wrapmanager Inc. purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at $252,000. Advisors Capital Management LLC lifted its position in IDEXX Laboratories by 1,276.4% in the second quarter. Advisors Capital Management LLC now owns 7,708 shares of the company’s stock worth $4,134,000 after buying an additional 7,148 shares during the last quarter. Finally, Clearstead Trust LLC boosted its stake in IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after buying an additional 16 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. UBS Group increased their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. BTIG Research raised their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Trading Down 1.6%

IDXX opened at $689.93 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock’s fifty day moving average is $651.74 and its two-hundred day moving average is $588.77. The company has a market capitalization of $55.09 billion, a P/E ratio of 57.45, a PEG ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. This trade represents a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.